

- 2. What is the molecular mechanism for the genotype-phenotype relationship in EDMD?
- 3. How would you plan for the antenatal diagnosis of Case IV: 4?
- 4. What is the possible explanation for having the predominant musculoskeletal findings with mutations of LAMA1 leads to EDMD2/3?



## **Clinical phenotypes:**

EDMD: a triad of weakness of girdle muscles (**the shoulder and the pelvic**), contractures (**the elbows, neck, and Achilles tendon**), and cardiac involvement (**dilated cardiomyopathy & arrhythmias**). In selected cases, cardiomyopathy could be present earlier. Significant inter- and intrafamilial variability even for the similar mutation.

(Key findings help to distinguish EDMD from the Becker: Absence of muscle pseudohypertrophy, association of the forearm muscles, cardiac conduction defects, and development of early contractures in involvement of the neck or paravertebral muscles.

## Two broad phenotypes for EDMD2 (AD) inheritance:

Phenotypes	Clinical findings*	Molecular Mechanism
Milder	Late onset and a mild degree of weakness and contractures	Haploinsufficiency
Severe	Early presentation and a rapidly progressive course	Dominant-negative or toxic gain-of-function

\*An increased frequency of sudden death in both groups

## Phenotypic Series - PS310300: Emery-Dreifuss muscular dystrophy – eight entries

EMD & FHL1 [X (1, 6 & XMPMA\*), LMNA [AD (2) & AR (3)], SYNE 1 & 2[(4, 5) AD], TMEM43 [(7), AD].

- Genes are primarily components of the nuclear envelope protein, which coordinates nuclear-cytoplasmic communication

\*Myopathy, X-linked, with postural muscle atrophy

**Counsel the family for antenatal diagnosis of case IV: 4**- Before planning for antenatal testing, the proband must be tested (case IV:2), but in this family, "isolated arrhythmias" need to be investigated (cases II:2, III:2, and III:3) for proper antenatal testing. If variants have been detected, then the mother (case III:4) and the fetus (amniotic fluid) samples have to be planned together because of the time-bound test. Meanwhile, clinical and lab data need to be collected for case III:2 and case III:2 for further analysis to know the extent of disease phenotype and variable presentation. Evidence-based data helps in the overall genetic counselling process.

## **Thought Riveting:**

- What are the differences between a Genogram and a Pedigree?
- Is there any possible therapeutic role of Crenolanib in EDMD?
- What are the specific repertoire variances between LMNA A/C in EDMD?
- What epigenetic cascades transpire with the malfunctioning of the LINC complex?
- What are the progeria features that need to be monitored in LMNA-related EDMD?